Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The field of oncology is rapidly advancing, driven by innovations in targeted therapies that address the specific molecular drivers of cancer. Pelitinib, also known by its research code EKB-569, is a prime example of such an innovation, functioning as a potent irreversible pan-ErbB tyrosine kinase inhibitor. Its role in kinase inhibitor research and oncology drug discovery is substantial, and NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting this vital scientific endeavor by supplying high-quality Pelitinib as a crucial pharmaceutical intermediate.
The mechanism of action for Pelitinib is centered on its ability to irreversibly bind to and inhibit the Epidermal Growth Factor Receptor (EGFR) family, specifically ErbB-1, ErbB-2, and ErbB-4. This precise inhibition of tyrosine kinase activity disrupts critical intracellular signaling cascades that are crucial for cancer cell proliferation and survival. By blocking these pathways, Pelitinib induces apoptosis (programmed cell death) in cancer cells and halts tumor progression, representing a sophisticated approach in drug development for solid tumors. The irreversible binding ensures sustained blockade of these oncogenic signals.
As a vital pharmaceutical intermediate, Pelitinib is fundamental to the advancement of kinase inhibitor research chemicals. Researchers utilize high-purity compounds like Pelitinib to explore new therapeutic strategies, understand resistance mechanisms, and optimize treatment regimens. NINGBO INNO PHARMCHEM CO.,LTD. provides Pelitinib to facilitate these critical studies, ensuring that scientists have access to reliable materials that underpin groundbreaking oncology drug discovery. The meticulous quality control applied to our products guarantees the accuracy and reproducibility of research findings.
Moreover, Pelitinib contributes significantly to the broader understanding of the EGFR signal transduction pathway. This knowledge is essential for identifying predictive biomarkers and developing personalized treatment strategies for cancer patients. Ongoing investigations are exploring Pelitinib's utility in combination therapies, aiming to enhance efficacy and overcome treatment resistance, further positioning it as a key molecule in the future of cancer management. Its impact on the development of advanced cancer treatments is undeniable.
In summary, Pelitinib (EKB-569) is a pivotal compound in the evolution of targeted cancer therapies. Its function as an irreversible pan-ErbB tyrosine kinase inhibitor places it at the forefront of kinase inhibitor research and oncology drug discovery. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supporting the scientific community by supplying essential pharmaceutical intermediates such as Pelitinib, thereby contributing to the creation of more effective and innovative cancer treatments.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
